AI & Drug Discovery
AI-Driven Drug Discovery Moves From Experiment to Enterprise
AI is moving deeper into target identification, molecule design, preclinical modeling and portfolio decisions.
Read full article →100 Industry Developments
Long-form editorial coverage across the modern pharmaceutical lifecycle.
Clinical Trials
Real-Time Clinical Trials and Continuous Regulatory Data
Regulators are testing ways to receive clinical-trial signals faster and improve decision-making during development.
Read full article →
Cell & Gene Therapy
Genome Editing Guidance Reshapes Cell and Gene Therapy Development
New regulatory thinking is emphasizing reusable platform knowledge and standardized genome-editing safety assessment.
Read full article →
Metabolic Health
The Next Generation of GLP-1 Medicines
GLP-1 innovation is expanding beyond injectable weight management into higher doses, oral formulations and broader metabolic strategies.
Read full article →
Metabolic Health
Oral GLP-1 Formulations Change the Obesity-Medicine Landscape
The move toward oral incretin therapies could broaden access, convenience and competitive dynamics in obesity care.
Read full article →
Metabolic Health
Higher-Dose Semaglutide and the Economics of Obesity Treatment
Higher-dose regimens illustrate how efficacy, manufacturing, tolerability and payer economics increasingly intersect.
Read full article →
Diabetes
Insulin Icodec and the Rise of Once-Weekly Diabetes Treatment
Longer-acting insulin technologies are changing how developers think about adherence, dosing frequency and diabetes care.
Read full article →
Regulatory & Approvals
First-in-Class and Novel Drug Approvals in 2026
The 2026 approval landscape shows continued innovation across rare disease, oncology, immunology and metabolic medicine.
Read full article →
Rare Disease
Rare-Disease Drug Development Becomes More Platform-Based
Regulators and developers are increasingly looking for ways to reuse validated science, manufacturing knowledge and clinical evidence.
Read full article →
Generics
AI Tools for Generic Drug Development
AI is being explored for formulation, bioequivalence, impurity assessment, manufacturing and regulatory workflows.
Read full article →
Digital Health
Digital Twins Enter Pharmaceutical Development
Digital twins are emerging as a way to model manufacturing, products and potentially elements of drug-development decision making.
Read full article →
AI Safety
AI and In-Silico Prediction of Drug-Induced Liver Injury
Regulatory qualification of computational tools marks a step toward more model-informed safety assessment.
Read full article →
Preclinical Innovation
New Approach Methodologies Reduce Dependence on Animal Testing
AI models, organ-on-chip systems and real-world data are becoming important components of modern nonclinical strategies.
Read full article →
Preclinical Innovation
Organ-on-Chip Platforms Gain Regulatory Relevance
Human-relevant microphysiological systems are moving from research laboratories toward practical drug-development workflows.
Read full article →
CMC
The Modernization of Chemistry, Manufacturing and Controls
Faster development is putting pressure on CMC organizations to build robust, flexible and data-rich processes earlier.
Read full article →
Manufacturing
Cell and Gene Therapy Manufacturing Becomes More Modular
Platform approaches and manufacturing standardization are increasingly important for complex biological medicines.
Read full article →
Oncology
Radiopharmaceuticals Become a Major Global Drug Development Frontier
Radiopharmaceuticals are expanding across imaging and targeted therapy while raising new manufacturing and supply-chain questions.
Read full article →
Oncology
Theranostics Connect Diagnosis and Targeted Treatment
The combination of molecular imaging and targeted radionuclide therapy is creating new development models.
Read full article →
Oncology
Next-Generation Cancer Vaccines
Personalized and platform-based cancer vaccines continue to push the boundary between immunology, sequencing and drug development.
Read full article →
Oncology
Personalized Oncology Enters a More Data-Intensive Era
Tumor profiling, biomarkers and computational analysis are increasingly central to treatment selection and trial design.
Read full article →
Biologics
Antibody-Drug Conjugates Continue Their Expansion
ADC innovation is moving toward new targets, payloads, linkers and combination strategies.
Read full article →
Biologics
Bispecific Antibodies Transform Immunotherapy Pipelines
Bispecific formats are creating new options for redirecting immune cells and simultaneously engaging multiple biological targets.
Read full article →
Biologics
The Rise of Multispecific Protein Therapeutics
Multispecific molecules are broadening the design space for targeted and immune-modulating medicines.
Read full article →
RNA Therapeutics
RNA Medicines Move Beyond the First Wave
RNA platforms are expanding beyond early successes into new tissues, targets, delivery systems and therapeutic concepts.
Read full article →
RNA Therapeutics
mRNA Platforms After the Vaccine Era
The maturation of mRNA manufacturing and delivery is opening new possibilities beyond infectious-disease vaccines.
Read full article →
RNA Therapeutics
siRNA and Gene-Silencing Medicines Expand
Longer-lasting gene-silencing approaches are enabling drug developers to revisit targets that were previously difficult to modulate.
Read full article →
RNA Therapeutics
Antisense Oligonucleotides Find New Niches
Antisense platforms are developing through improved chemistry, delivery and increasingly precise genetic targets.
Read full article →
Small Molecules
Protein Degraders Become a Major Small-Molecule Strategy
Targeted protein degradation is expanding the range of proteins that drug developers can potentially control.
Read full article →
Small Molecules
Molecular Glues Open a New Route to Undruggable Targets
Molecular glues offer a distinct pharmacology for recruiting cellular machinery to eliminate selected proteins.
Read full article →
Small Molecules
Covalent Drugs Return With Greater Precision
Modern covalent drug design combines irreversible chemistry with increasingly sophisticated selectivity and safety strategies.
Read full article →
Immunology
Precision Immunology Rewrites Autoimmune Drug Development
Biomarkers and targeted mechanisms are pushing immunology toward more differentiated treatment strategies.
Read full article →
Immunology
New JAK and Cytokine Strategies in Inflammatory Disease
Developers are refining pathway selectivity, tissue targeting and risk management in inflammatory medicines.
Read full article →
Dermatology
The Changing Landscape of Dermatology Drugs
Biologics, small molecules and targeted immune therapies are reshaping treatment options across skin diseases.
Read full article →
Drug Delivery
Long-Acting Injectables Expand Beyond Antipsychotics
Depot and extended-release technologies are being applied across therapeutic areas to improve adherence and exposure control.
Read full article →
Drug Delivery
Drug Delivery Moves Toward Smarter Depots
New depot technologies aim to control release kinetics while improving convenience and reducing dosing burden.
Read full article →
Drug Delivery
Microneedles and Transdermal Drug Delivery Mature
Microneedle platforms are being developed to make systemic and local delivery more convenient.
Read full article →
Drug Delivery
Oral Peptides Become a Strategic Goal
The pharmaceutical industry is investing heavily in technologies that can make large-molecule therapies easier to take by mouth.
Read full article →
Drug Delivery
The Global Race for Better Biologics Delivery
Delivery technology is becoming a competitive differentiator as biologic pipelines grow more sophisticated.
Read full article →
Biosimilars
Biosimilars Enter a More Mature Commercial Phase
The biosimilar market is shifting from early adoption toward broader portfolio strategy, competition and lifecycle management.
Read full article →
Generics
Complex Generics Become a Scientific Priority
Complex generics require more advanced analytical, bioequivalence and formulation approaches than conventional generics.
Read full article →
Drug Safety
Nitrosamine Control Becomes a Long-Term Quality Discipline
Nitrosamine risk management is becoming embedded in pharmaceutical quality systems and product development.
Read full article →
Manufacturing
Continuous Manufacturing Gains Ground
Continuous processing promises tighter control, smaller footprints and potentially more flexible pharmaceutical production.
Read full article →
Manufacturing
Digital Manufacturing and Pharmaceutical Data Infrastructure
Connected equipment, data historians and advanced analytics are becoming foundations for modern drug manufacturing.
Read full article →
Manufacturing
AI/ML in Pharmaceutical Manufacturing Quality
Machine learning is being explored for process monitoring, anomaly detection, maintenance and quality decision support.
Read full article →
Supply Chain
Pharma Supply Chains Become a Strategic Innovation Area
Resilience is moving from procurement concern to executive-level product and manufacturing strategy.
Read full article →
Supply Chain
Domestic Drug Manufacturing and Supply Resilience
Governments and regulators are increasingly linking pharmaceutical manufacturing capacity with national resilience.
Read full article →
Supply Chain
The New Economics of Pharmaceutical Reshoring
Reshoring decisions increasingly weigh quality, resilience, automation, labor and policy incentives.
Read full article →
Logistics
Cold-Chain Innovation for Advanced Medicines
Cell therapies, biologics and sensitive vaccines are driving demand for better temperature monitoring and logistics.
Read full article →
Precision Medicine
Personalized Medicine and Companion Diagnostics
Drug development is increasingly intertwined with diagnostic technologies that identify the right patient populations.
Read full article →
Clinical Trials
Biomarker-Driven Clinical Trials Become Standard Practice
Biomarkers are helping developers enrich populations, stratify risk and improve the information generated by trials.
Read full article →
Clinical Evidence
Real-World Evidence Moves Closer to Core Development
Real-world data is increasingly being used alongside conventional trials to answer questions across the product lifecycle.
Read full article →
Digital Health
Wearable Devices in Drug Development
Connected sensors can generate frequent patient-level measurements that complement traditional clinical endpoints.
Read full article →
Clinical Trials
Decentralized Clinical Trials Enter Their Next Phase
Hybrid and decentralized models are evolving toward more selective use of remote tools where they genuinely improve participation or data quality.
Read full article →
Clinical Trials
Synthetic Control Arms and External Data
External datasets can potentially reduce trial burden when carefully validated and matched to the scientific question.
Read full article →
Clinical Trials
Adaptive Trial Designs Gain Practical Importance
Adaptive methods can help developers make preplanned changes while preserving statistical integrity.
Read full article →
Clinical Trials
Platform Trials Change Oncology Research
Shared controls and modular trial structures can evaluate multiple interventions more efficiently in selected settings.
Read full article →
Clinical Trials
Master Protocols Across Therapeutic Areas
Master protocols provide a framework for testing multiple hypotheses under coordinated governance.
Read full article →
Clinical Trials
Patient-Centric Trial Design
Developers are increasingly designing trials around participant burden, accessibility and meaningful outcomes.
Read full article →
Clinical Trials
Digital Endpoints Become More Credible
Sensor-derived and app-based measures are being evaluated more rigorously as potential clinical endpoints.
Read full article →
Regulatory Science
Regulatory Science Enters the AI Era
Agencies are developing frameworks for evaluating computational tools, AI-supported development and new evidence sources.
Read full article →
AI Governance
AI Governance in Pharmaceutical R&D
Pharmaceutical organizations are building governance systems for validation, traceability, human oversight and model risk.
Read full article →
AI & Operations
Generative AI for Medical Writing and Regulatory Operations
Generative AI is increasingly used for drafting, summarization and knowledge work, with strong requirements for review and provenance.
Read full article →
Drug Safety
AI-Assisted Pharmacovigilance
Machine learning and language models can help process large volumes of safety information while retaining human oversight.
Read full article →
Regulatory Operations
Automation of Regulatory Submissions
Structured data and automation are reducing manual work across submission preparation, publishing and lifecycle management.
Read full article →
Regulatory Operations
Digital Transformation of Regulatory Affairs
Regulatory teams are moving toward connected data, standardized content and more proactive information management.
Read full article →
Regulatory Policy
Global Harmonization of Drug Development
Sponsors increasingly design programs for multiple regulators, making alignment of scientific expectations more important.
Read full article →
Regulatory Policy
ICH Modernization and the Future of Quality
International standards continue to evolve as manufacturing science, analytics and development models change.
Read full article →
Regulatory Policy
The European Regulatory Shift Toward Digital Submissions
EMA's move of initial marketing authorization applications to IRIS is part of a broader digital regulatory transition.
Read full article →
Data & Analytics
Pharmaceutical Data Standards Become Strategic Assets
Common data structures are essential for connecting discovery, trials, manufacturing and regulatory processes.
Read full article →
Data & Analytics
Knowledge Graphs for Drug R&D
Knowledge graphs can connect targets, molecules, studies, diseases and evidence across fragmented scientific systems.
Read full article →
Data & Analytics
Cloud Computing in Pharmaceutical Research
Cloud platforms are becoming infrastructure for large-scale analysis, collaboration and AI-enabled research.
Read full article →
Data & Analytics
Federated Learning for Sensitive Health Data
Federated approaches may allow model development across institutions without centralizing all underlying data.
Read full article →
Data & Analytics
Privacy-Preserving Analytics in Drug Development
Privacy-enhancing methods are increasingly relevant as pharmaceutical organizations use richer clinical and real-world datasets.
Read full article →
Oncology
New Approaches to Rare Cancer Trials
Small populations are encouraging innovative trial designs, biomarker strategies and international collaboration.
Read full article →
Rare Disease
Accelerating Drug Development for Pediatric Diseases
Better natural-history data, biomarkers and regulatory flexibility are helping address difficult pediatric development challenges.
Read full article →
Cell & Gene Therapy
The New Era of Gene Therapy Follow-Up
Long-term monitoring is becoming a central operational and scientific consideration for durable genetic medicines.
Read full article →
Cell & Gene Therapy
Genome Editing Safety and Off-Target Assessment
Modern sequencing and analytical methods are improving how developers characterize genome-editing risks.
Read full article →
Cell & Gene Therapy
Base Editing and Prime Editing Development
New editing architectures are expanding the possible precision and scope of genetic interventions.
Read full article →
Cell & Gene Therapy
In Vivo Gene Editing Advances
Delivering editing systems directly in the body could simplify treatment logistics while creating new delivery and safety questions.
Read full article →
Cell & Gene Therapy
Allogeneic Cell Therapy Platforms
Off-the-shelf cell products aim to reduce manufacturing time and expand access to cellular medicines.
Read full article →
Advanced Biomedicine
Engineered Living Materials in Therapeutics
Engineered living systems could produce or release therapeutic substances in place, creating novel regulatory questions.
Read full article →
Precision Medicine
The Expanding Role of Pharmacogenomics
Genetic variation is increasingly being integrated into drug selection, dosing and safety strategies.
Read full article →
Data & Analytics
Multi-Omics in Drug Discovery
Combining genomics, proteomics, metabolomics and other layers can improve target selection and biological understanding.
Read full article →
Data & Analytics
Single-Cell Data Changes Drug Discovery
Single-cell technologies reveal biological heterogeneity that can inform targets, biomarkers and mechanisms.
Read full article →
Data & Analytics
Spatial Biology Enters Translational Drug Development
Spatial methods connect molecular information with tissue architecture, creating new opportunities for translational research.
Read full article →
Regulatory Science
The New Role of Biomarker Qualification
Qualified biomarkers can reduce uncertainty and support more consistent development decisions across programs.
Read full article →
AI & Drug Discovery
Drug Repurposing With AI and Real-World Data
Computational methods can identify new relationships among existing medicines, diseases and patient populations.
Read full article →
AI & Biologics
De Novo Protein Design and Therapeutics
Generative protein design is expanding the engineering space for antibodies, binders and other therapeutic proteins.
Read full article →
AI & Drug Discovery
Structure-Based Drug Design in the AI Era
Better structural models and machine learning are accelerating parts of the molecular-design cycle.
Read full article →
AI & Drug Discovery
Virtual Screening at Global Scale
Modern computational screening can prioritize chemical space before expensive laboratory experiments.
Read full article →
Automation
The Convergence of Robotics and Drug Discovery
Laboratory automation is connecting high-throughput experimentation with computational design and closed-loop learning.
Read full article →
Automation
Self-Driving Laboratories for Pharmaceutical Research
Autonomous experimentation aims to shorten design-build-test cycles and improve reproducibility.
Read full article →
Sustainability
Pharmaceutical Sustainability and Green Chemistry
Drug developers are applying greener chemistry and manufacturing principles to reduce waste and energy intensity.
Read full article →
Sustainability
Biocatalysis and More Sustainable API Manufacturing
Enzymatic processes can offer selective, efficient routes to complex pharmaceutical building blocks.
Read full article →
Sustainability
Water and Energy Efficiency in Drug Manufacturing
Manufacturers are treating resource efficiency as both an environmental and operational priority.
Read full article →
Manufacturing
The Future of Pharmaceutical Packaging
Packaging innovation is balancing stability, sustainability, serialization and patient usability.
Read full article →
Supply Chain
Serialization and Traceability in Global Medicine Supply
Digital traceability is becoming increasingly important for counterfeit prevention, recalls and supply visibility.
Read full article →
Precision Medicine
The Next Generation of Personalized Dosing
Pharmacokinetic modeling, sensors and patient data are supporting more individualized dosing strategies.
Read full article →
Drug Delivery
Long-Acting Treatments and Adherence
Reducing dosing frequency can change treatment persistence, healthcare utilization and patient experience.
Read full article →
Business & Innovation
Pharma Partnerships With AI Companies
Drug companies are forming partnerships to access specialized models, infrastructure and computational capabilities.
Read full article →No articles match your search.
AdvertisementDRUG.SE PREMIUM INDUSTRY PARTNERReach pharmaceutical and biotech professionals.
What Drug.se covers
From molecule design to manufacturing, regulation and market impact.
01
Discovery & AI
AI, computational chemistry, protein design, data science and laboratory automation.
02
Clinical & Regulatory
Clinical trials, biomarkers, real-world evidence, regulatory science and digital endpoints.
03
Manufacturing & Supply
CMC, quality, advanced therapies, continuous manufacturing and supply resilience.
About Drug.se
Drug.se is an independent editorial publication designed for readers who want a clear view of how pharmaceutical science, regulation, technology and business are converging. Articles are structured around industry context, technical implications, clinical evidence, regulatory considerations, manufacturing, commercial impact and outlook.
Drug.se does not provide medical advice. Because drug approvals, safety information and policy can change, readers should verify current status through official regulators and primary scientific sources.
Drug.se Briefing
Get the weekly pharmaceutical intelligence briefing
A concise digest of important drug-development, regulatory, manufacturing and biotech developments.
Official reference sources
Drug.se prioritizes official regulatory and scientific reference material.